Among the list of 68 customers, 44 had been intense myeloid leukemia, 24 had been surface immunogenic protein intense lymphoblastic leukemia, 39 had been male, 29 were feminine plus the median age was 41(13-75) yrs old. The 68 patients obtained 242 times during the chemotherapy or hematopoietic stem cellular transplantation(HSCT), including 73 times during the preliminary chemotherapy or inducting chemotherapy after recurrence, 14 times of HSCT, 155 times during the consolidating chemotherapy. Patients got 152 times during the anti-fungal prophylaxis, including 77 times during the main anti-fungal prophylaxis and 75 times of additional anti-fungal prophylaxis. Finaln other regions at homeland and overseas. Anti-fungal prophylaxis must be directed at the patients with AL who have the high risk facets of inducting chemotherapy or HSCT, time of agranulocytosis ≥7 times and risk stratification of high-risk. To analyze the medical attributes of severe myeloid leukemia clients with hemophagocytic problem. The medical data of 2 customers with severe myeloid leukemia difficult with hemophagocytic problem were collected, together with medical qualities and treatment outcomes were reviewed. There were two customers with severe myeloid leukemia, including 1 male and 1 female，aged for 67 and 40 years old，respectively. Hemophagocytic syndrome occurred in one patient after induction treatment for acute myeloid leukemia and another patient after consolidation therapy. Both of Plant genetic engineering the patients with hemophagocytic syndrome revealed temperature, hemocytopenia, high ferritin, large titer sCD25 levels and hemophagocytes in bone tissue marrow. After accomplished anti-infection, glucocorticoid, human being immunoglobulin and etoposide regimens treatment, hemophagocytic problem ended up being controlled in both of the two customers. One patient neglected to induce acute myeloid leukemia and another patient achieved complete remission. Acute myeloid leukemia complicated with hemophagocytic problem is unusual. Early identification, early anti-infection along with HLH94 regimen can control hemophagocytosis and improve prognosis.Acute myeloid leukemia complicated with hemophagocytic syndrome is rare. Early identification, early anti-infection coupled with HLH94 regime can get a handle on hemophagocytosis and enhance prognosis. To research the effect of PPP2R5C into the task of Molt-4 cells in youth acute T lymphocytic leukemia and its own apparatus. The tiny interfering RNA (siRNA) technology focusing on PPP2R5C gene ended up being familiar with down-regulate the expression of PPP2R5C in Molt-4 cells. On top of that, a blank control group, a bad control team and a 17-DMAG team were put up. The cells when you look at the bad control team were transfected with siRNA-NC, the cells in 17-DMAG group were treated because of the HSP90 inhibitor 17-DMAG at one last focus of 6.4 μmol/L for 48 h. Real time fluorescent quantitative PCR (RT-qPCR) and Western blot were used to detect transfection effectiveness; CCK-8 method had been made use of to detect the proliferation task of this cells in each team, EdU was used to identify the expansion degree of the cells in each group, flow cytometry was made use of to detect the cell cycle circulation ratio associated with the cells in each group, Annexin V-FITC/PI staining was made use of to identify the apoptosis of this cellular, RT-qPCR and Wester<0.05). The expressions of PPP2R5C mRNA and protein into the 17-DMAG group were additionally significantly down-regulated weighed against those in the blank control team and si-NC group (P<0.05). The phrase of CD68 in bone tissue marrow blast cells ended up being recognized by four-color circulation cytometry in 50 newly diagnosed AML patients and 23 settings. The expression of CD68 in peripheral bloodstream of 85 newly identified AML clients see more , 29 remission AML patients and 24 settings ended up being detected by ELISA. The correlation involving the appearance price of non-M3 AML bone tissue marrow CD68, peripheral blood CD68 concentration and white blood cell count and other medical data had been contrasted respectively. The median CD68 expression price in myeloid leukemia cells of non-M3 AML clients was 19.7%, considerably greater than control (0.2%) (P<0.001). The median concentration of non-M3 CD68 in peripheral bloodstream was 67.97 pg/ml, notably higher than in control (29.94 pg/ml)（P<0.01）. There was clearly no statistically factor in the plasma CD68 concentration regarding the peripheral bloodstream n level of CD68 is correlated with therapy reaction. The clinical data of 28 customers with risky AML treated by cladribine in combination with busulfan plus cyclophosphamide (BuCy) intensified conditioning regimen before allogeneic hematopoietic stem cellular transplantation (allo-HSCT) in Zhujiang Hospital, Southern Medical University from October 2016 to Summer 2020 were analyzed retrospectively. The overall survival (OS) rate, collective progression-free survival (PFS) price, relapse price, non-relapse mortality (NRM), regimen relevant toxicity (RRT) and danger factors affecting prognosis regarding the clients had been examined. The 1-year OS and PFS of this clients after implantation was (78.8±8.6)% and (79.8±8.1)%, as the 1-year cumulative relapse rate and NRM associated with clients ended up being 9.3% and 22.0%, respectively. The 1-year expected OS of MRD risky customers before HSCT was 10atients before HSCT can perform much better transplant benefits, but the prognosis of patients with relapse before transplantation is certainly not somewhat improved. Consequently, for non-relapsed high-risk AML patients, this intensified training regimen has a right to be considered.